2019 AASLD Abstract Categories and Descriptors (The Liver Meeting®)

1. Acute Liver Failure and Artificial Liver Support
   AO1 Acute Liver Failure and Artificial Liver Support

2. Advanced Practice Providers (NP, PA, RN, pharmacists, etc.)
   BO1 Behavioral and Quality Issues
   BO2 Practice Issues

3. Alcoholic Liver Diseases: Clinical and Experimental
   CO1 Alcoholic Liver Diseases: Clinical and Experimental

4. Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis
   DO1 Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts
   DO2 Cholangiocyte Biology
   DO3 Experimental Cholestasis

5. Cell and Molecular Biology
   EO1 Cell Structure and Function
   EO2 Signal Transduction and Nuclear Receptors
   EO3 Gene Expression and Therapy
   EO4 Stem Cell Biology

6. Genomics and Precision Medicine
   FO1 Genomics and Precision Medicine

7. Gut Liver Axis and Microbiome
   GO1 Gut Liver Axis and Microbiome

8. Health Services Research
   HO1 Health Care Delivery/Access/Quality
   HO2 Cost-Effectiveness and Economics of Care
   HO3 Patient Centered Outcomes Research

9. Hepatitis B
   IO1 Virology, Pathogenesis, and Immunology
   IO2 Diagnostics and Biomarkers
   IO3 Epidemiology, Prevention, Natural History
   IO4 Therapeutics – Approved Agents
   IO5 Therapeutics – New Agents

10. Hepatitis C
    JO1 Virology, Pathogenesis, and Immunology
    JO2 Diagnostics, Epidemiology, and Natural History
    JO3 Therapeutics – New Agents
    JO4 Therapies – General Populations
    JO5 Therapies – Unique Populations

11. Hepatitis (non-B, non-C)
    KO1 Hepatitis – Other Infections
12. Hepatobiliary Neoplasia
   LO1 Experimental Hepatocarcinogenesis
   LO2 Diagnostics and Liver Imaging
   LO3 Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

13. Hepatotoxicity
   MO1 Pathogenesis and Mechanisms
   MO2 Drug Metabolism, Toxicity and Therapeutics
   MO3 Predictors of Drug Toxicity

14. Human Cholestatic and Autoimmune Liver Diseases
   NO1 PBC/PSC and Other Cholestatic Disease
   NO2 Autoimmune Liver Disease

15. Inflammation and Immunobiology
   OO1 Animal Models
   OO2 Innate Immunity
   OO3 Adaptive Immunity
   OO4 Mechanisms of Injury

16. Liver Fibrogenesis and Non-Parenchymal Cell Biology
   PO1 Basic Fibrosis Research and Stellate Cell Biology
   PO2 Imaging and Noninvasive Markers of Liver Disease
   PO3 Clinical and Translational Fibrosis Research

17. Liver Transplantation and Liver Surgery
   QQ1 Cellular Immunobiology, Preservation, and Cell Transplantation
   QQ2 Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
   QQ3 Immunosuppression, Outcomes, Complications
   QQ4 Viral Hepatitis

18. Metabolic and Genetic Disease
   RO1 Hemochromatosis, Wilson Disease, and α-1 Antitrypsin Deficiency

19. NAFLD and NASH
   SO1 Experimental – Basic
   SO2 Experimental – Clinical
   SO3 Epidemiology, and Natural History, Prevention and Outcomes
   SO4 Diagnostics and Biomarkers
   SO5 Therapeutics – Pharmacologic and Other

20. Pediatric Hepatology
   TO1 Pediatric Liver Disease – Basic Science
   TO2 Biliary Atresia and Cholestasis
   TO3 Viral and Autoimmune Hepatitis
   TO4 Metabolic and Genetic Diseases
   TO5 Pediatric Liver Transplantation
21. Portal Hypertension and Other Complications of Cirrhosis
   UO1 Experimental
   UO2 Ascites, Renal Dysfunction, and Hepatorenal Syndrome
   UO3 Varices and Bleeding
   UO4 Encephalopathy and Other Complications
   UO5 Infections and Acute on Chronic Liver Failure

22. Training and Education (Career Development)
   VO1 Training and Education (Career Development)